Carvedilol Tablet/Capsules Suppliers & Bulk Manufacturers
Available Forms: Tablet/Capsules
Available Strengths: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg
Reference Brands: Coreg(US & EU)
Category:
Heart Disorder
Carvedilol is a non-selective beta-blocker with alpha-1 blocking activity, which reduces heart rate, blood pressure, and myocardial oxygen demand. It improves cardiac output and decreases sympathetic nervous system activity. Benefits include controlling hypertension, managing heart failure, reducing post-MI mortality, and improving overall cardiovascular health and survival outcomes.
Carvedilol tablet/Capsules is available in Tablet/Capsules
and strengths such as 3.125 mg, 6.25 mg, 12.5 mg, 25 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Carvedilol tablet/Capsules is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Carvedilol tablet/Capsules can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Carvedilol tablets are approved in the US by the FDA and in the EU via EMA for treating hypertension, heart failure, and post-myocardial infarction. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing quality, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical trial and manufacturing data, while the EMA ensures regional safety and quality compliance. For guidance on dossier preparation, regulatory pathways, and market access strategies, visit PharmaTradz. Ensuring compliance supports timely approval, safe use, and global availability of carvedilol tablets, helping improve cardiovascular outcomes and patients’ quality of life worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing